摘要
目的：评价手术联合米非司酮治疗子宫内膜异位症（内异症）的近、远期疗效。方法：回顾性分析本院施行手术治疗的126例内异症患者的病例资料，其中Ⅰ、Ⅱ期患者28例，Ⅲ期73例，Ⅳ期25例。保守手术96例，半保守手术30例；92例术后连续6月服用米非司酮10mg·d^-1，34例未服药，所有患者均随访3～5年。结果：米非司酮组患者的完全缓解（CR）率为77．2％，部分缓解率（PR）为22．8％，复发率为16．3％；未服．药组患者52．9％CR，47．1％PR，32．4％复发；两组间差异有统计学意义（P〈0．05）。米非司酮组副反应发生率为17．4％，消除残余病灶的有效率为89．1％。治疗前及治疗后复发患者的血清雌二醇（E2）、孕激素（P）、肿瘤相关抗原125（CA125）水平均显著高于治疗后（P〈0．05）。结论：手术是内异症的基本治疗手段，而米非司酮用于内异症术后巩固，能显著降低复发率，并维持血清标志物处于正常水平．
AIM： To evaluate the therapeutic effect of treatment with surgery and mifepristone in patients with endometriosis. METHODS： The medical records of 126 endometriosis patients undergoing surgical operation were analyzed retrospectively. There were 28 cases in stage Ⅰ or Ⅱ , 73 cases in stage Ⅲ, and 25 cases in stage Ⅳ. Conservative surgery was performed in 96 cases and semiconservative surgery in 30 cases. Postoperation, 92 cases continued taking 10 mg·d^- 1 of mifepristone for 6 months and 34 cases did not. All patients received 3 to 5 years follow up. RESULTS： The complete remission （CR） rate in mifepristone group was 77.2%, partial remission （PR） rate was 22.8 %, and recurrence rate was 16.3 %. The CR of controls was 52.9%, PR was 47. 1%, and recurrence rate was 32.4%. There was significant difference between two groups （ P 〈 0.05）. The side effect of mifepristone occurred in 17.4% of all patients, but it eliminated the remained lesions in 89.1% of all patients.The levels of estradiol, progestin and CA125 in senma from pretreatment or recurrent patients were significantly higher than the patients with posttreatment of mifepristone （P 〈 0.05）. CONCLUSION： Surgery is the principal method for treating endometriosis. Taking mifepfistone can improve the prognosis, and decrease the recurrence rate, and maintain the serum markers at normal levels.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2006年第5期593-595,共3页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
子宫内膜异位症
手术
米非司酮
疗效
endometriosis
surgery
mifepristone
therapeutic effect
